1. Generic Drugs. Overview & Basics. FDA. 2017. Available from: https://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/GenericDrugs/ucm567297.htm [Accessed: 25 January 2019]
2. Generic and hybrid medicines. European Medicines Agency. Available from: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/generic-hybrid-medicines [Accessed: 25 January 2019]
3. Marketing Authorization of Pharmaceutical Products with Special Reference to Multisource (Generic) Products: A Manual for Drug Regulatory Authorities—Regulatory Support Series No. 005. WHO. Available from: http://apps.who.int/medicinedocs/en/d/Js2273e/ [Accessed: 31 January 2019]
4. Ahmed I, Kaspar B, Sharma U. Biosimilars: Impact of biologic product life cycle and European experience on the regulatory trajectory in the United States. Clinical Therapeutics. 2012;34(2):400-419. DOI: 10.1016/j.clinthera.2011.12.005
5. Nabhan C, Parsad S, Mato AR, Feinberg BA. Biosimilars in oncology in the United States: A review. JAMA Oncology. 2018;4(2):241-247. DOI: 10.1001/jamaoncol.2017.2004